Pfizer Inc. (NYSE:PFE) Shares Bought by Calamos Advisors LLC

Calamos Advisors LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,776,366 shares of the biopharmaceutical company's stock after purchasing an additional 133,792 shares during the quarter. Calamos Advisors LLC's holdings in Pfizer were worth $45,013,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. acquired a new position in Pfizer in the first quarter valued at $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer during the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE:PFE traded up $0.13 during mid-day trading on Friday, reaching $25.45. The stock had a trading volume of 27,104,580 shares, compared to its average volume of 41,625,077. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The business has a 50 day simple moving average of $23.67 and a 200 day simple moving average of $24.84. The firm has a market capitalization of $144.66 billion, a price-to-earnings ratio of 18.44, a PEG ratio of 0.92 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the firm earned $0.82 EPS. The company's quarterly revenue was down 7.8% compared to the same quarter last year. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.76%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PFE. Leerink Partners reduced their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Redburn Atlantic decreased their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Morgan Stanley raised their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, BMO Capital Markets reduced their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.